H2 Equity Partners (“H2”) is pleased to announce it has exchanged contracts to acquire Optegra International Limited (“Optegra”). Completion of the acquisition will occur following satisfaction of certain regulatory conditions and is expected to take place early in 2021.
Optegra is a leading pan-European ophthalmology group with 23 eye hospitals across the United Kingdom, Czech Republic and Poland. Optegra provides a range of critical eye-care services including cataract surgeries and AMD as well as leading innovative vision correction procedures. The business provides leading eye-care to publicly funded national healthcare systems such as the NHS as well as to self-pay patients. The group holds top-3 market positions in each of the countries in which it operates. Optegra has an exceptional management team, leading surgeons and clinical teams, and well invested facilities with ample capacity to support future growth.
Following H2’s investment, management, led by CEO Dr Peter Byloos, will work closely with H2 to deliver Optegra’s ambitious growth strategy and ensure it continues to provide excellent care and service to its patients.
For further information on Optegra please refer to www.optegra.com
